AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare metabolic diseases,
today announced that it will host an investor conference call and
webcast tomorrow morning to discuss the topline results from the
PEACE Phase 3 clinical trial of pegzilarginase in patients with
Arginase 1 Deficiency (ARG1-D).
Investors and the public are invited to listen to a live audio
webcast of the conference call on December
6, 2021, at 8:00am ET, which
can be accessed prior to the start of the call by dialing
1-877-425-9470 (U.S.) or 1-201-389-0878 (International) Conference
ID 13725511 or through the Events & Presentations section of
the Company's website.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology
company redefining the potential of human enzyme therapeutics to
benefit people with rare metabolic diseases with limited treatment
options. Aeglea's lead product
candidate, pegzilarginase, is in an
ongoing Phase 3 pivotal trial in patients with Arginase 1
Deficiency and has received both Rare Pediatric Disease and
Breakthrough Therapy Designations. Aeglea has an ongoing
Phase 1/2 clinical trial of AGLE-177 for the treatment of
Homocystinuria. AGLE-177 has been granted Rare Pediatric
Disease Designation. Aeglea has an active discovery
platform focused on engineering small changes in human enzymes to
have a big impact on the lives of patients and their families. For
more information, please visit http://aeglea.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-host-conference-call-to-report-phase-3-topline-results-of-pegzilarginase-in-patients-with-arginase-1-deficiency-301437580.html
SOURCE Aeglea BioTherapeutics, Inc.